Cargando…

Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions

BACKGROUND: Comorbidities can complicate the management of severe asthma; therefore, the presence of comorbid conditions or traits often need to be considered when considering treatment options for patients with severe asthma. The aim of this analysis is to investigate the efficacy of mepolizumab in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gibson, Peter G., Prazma, Charlene M., Chupp, Geoffrey L., Bradford, Eric S., Forshag, Mark, Mallett, Stephen A., Yancey, Steve W., Smith, Steven G., Bel, Elisabeth H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8182929/ https://www.ncbi.nlm.nih.gov/pubmed/34098955 http://dx.doi.org/10.1186/s12931-021-01746-4

Ejemplares similares

Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes
por: Prazma, Charlene M, et al.
Publicado: (2021)

Update: Mepolizumab treatment in patients with severe eosinophilic asthma and prior omalizumab use
por: Albers, Frank C., et al.
Publicado: (2019)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
por: Yancey, Steven W., et al.
Publicado: (2019)

Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment
por: Magnan, A., et al.
Publicado: (2016)

Oral corticosteroid dose changes and impact on peripheral blood eosinophil counts in patients with severe eosinophilic asthma: a post hoc analysis
por: Prazma, Charlene M., et al.
Publicado: (2019)

Eosinophil‐derived neurotoxin and clinical outcomes with mepolizumab in severe eosinophilic asthma
por: Howarth, Peter, et al.
Publicado: (2020)

Health outcomes after stopping long-term mepolizumab in severe eosinophilic asthma: COMET
por: Liu, Mark C., et al.
Publicado: (2022)

Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab
por: Pavord, Ian D., et al.
Publicado: (2022)

Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma
por: Gupta, Atul, et al.
Publicado: (2019)

Development of methodology for assessing steroid-tapering in clinical trials for biologics in asthma
por: Korn, Stephanie, et al.
Publicado: (2022)

Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials
por: Lemiere, Catherine, et al.
Publicado: (2021)

Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study)
por: Moore, Wendy C., et al.
Publicado: (2022)

Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study
por: Pavord, Ian, et al.
Publicado: (2023)

Outcomes following mepolizumab treatment discontinuation: real-world experience from an open-label trial
por: Ortega, Hector, et al.
Publicado: (2019)

Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis
por: Harrison, Tim, et al.
Publicado: (2020)

Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA
por: Albers, Frank C., et al.
Publicado: (2019)

Severe Pediatric Asthma Therapy: Mepolizumab
por: Ullmann, Nicola, et al.
Publicado: (2022)

Real-life effectiveness of mepolizumab in patients with severe refractory eosinophilic asthma and multiple comorbidities
por: Crimi, Claudia, et al.
Publicado: (2020)

Fungal sensitization and its relationship to mepolizumab response in patients with severe eosinophilic asthma
por: Wardlaw, Andrew, et al.
Publicado: (2020)

Efficacy and safety of mepolizumab in Korean patients with severe eosinophilic asthma from the DREAM and MENSA studies
por: Kim, Mi-Kyeong, et al.
Publicado: (2021)

Clinical usefulness of mepolizumab in severe eosinophilic asthma
por: Menzella, Francesco, et al.
Publicado: (2016)

Response to mepolizumab treatment is sustained across 4-weekly dosing periods
por: Pavord, Ian D., et al.
Publicado: (2020)

Economic Burden of Illness Among Patients with Severe Asthma in a Managed Care Setting
por: Chastek, Benjamin, et al.
Publicado: (2016)

Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics
por: Liu, Mark C., et al.
Publicado: (2021)

Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO
por: Pavord, Ian D, et al.
Publicado: (2021)

Response to case report: Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy
por: Pouliquen, I. J., et al.
Publicado: (2017)

Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma
por: Haldar, Pranabashis
Publicado: (2017)

Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis
por: Numata, Takanori, et al.
Publicado: (2019)

Mepolizumab does not alter the blood basophil count in severe asthma
por: Wright, Adam Kelvin Alec, et al.
Publicado: (2019)

Role of mepolizumab in severe allergic asthma with vocal cord polyp
por: Karim, Azmat, et al.
Publicado: (2022)

The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma
por: Chapman, Kenneth R., et al.
Publicado: (2019)

From DREAM to REALITI‐A and beyond: Mepolizumab for the treatment of eosinophil‐driven diseases
por: Pavord, Ian D., et al.
Publicado: (2021)

Effect of benralizumab in a patient with uncontrolled severe eosinophilic asthma and comorbid chronic rhinosinusitis with nasal polyps refractory to mepolizumab treatment
por: Mansur, Adel H.
Publicado: (2021)

Self-Administered Mepolizumab in the Management of Severe Asthma: Usability and Patient Acceptance
por: Miyokawa, Reika, et al.
Publicado: (2020)

Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life()
por: Bagnasco, Diego, et al.
Publicado: (2021)

Outcomes over the first two years of treatment with mepolizumab in severe asthma
por: Elsey, Lynn, et al.
Publicado: (2021)

Dose-Response Relationship Between Long-Term Systemic Corticosteroid Use and Related Complications in Patients with Severe Asthma
por: Dalal, Anand A., et al.
Publicado: (2016)

Characterization of disease flares and impact of mepolizumab in patients with hypereosinophilic syndrome
por: Pane, Fabrizio, et al.
Publicado: (2022)

May mepolizumab used in asthma correct subfertility?
por: Ozden, Guzin, et al.
Publicado: (2021)

Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience
por: Varricchi, Gilda, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_mdkq35gnqg7bdr11jctt2ub6ot